138 related articles for article (PubMed ID: 37354986)
1. A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.
Wernick HJ; Wentzel E; Jackson K; Schmuhl K; Valenti O; Bonny AE; Berlan ED
J Pediatr Adolesc Gynecol; 2023 Dec; 36(6):549-552. PubMed ID: 37354986
[TBL] [Abstract][Full Text] [Related]
2. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
3. Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19.
Smith TJ; Urdanigo TK; Shroff N; Rubin SE
Contraception; 2023 Jul; 123():110008. PubMed ID: 36931548
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
Beasley A; White KO; Cremers S; Westhoff C
Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
[TBL] [Abstract][Full Text] [Related]
6. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
8. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
Williams RL; Hensel DJ; Fortenberry JD
Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
[TBL] [Abstract][Full Text] [Related]
9. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
[TBL] [Abstract][Full Text] [Related]
10. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
[TBL] [Abstract][Full Text] [Related]
11. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
[TBL] [Abstract][Full Text] [Related]
12. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
13. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
[TBL] [Abstract][Full Text] [Related]
14. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
16. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
[TBL] [Abstract][Full Text] [Related]
17. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
Prabhakaran S; Sweet A
Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
[TBL] [Abstract][Full Text] [Related]
18. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
19. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
Kohn JE; Berlan ED; Tang JH; Beasley A
Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
[TBL] [Abstract][Full Text] [Related]
20. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
